Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies: A Phase 1 Double Blinded Randomized Placebo Toxicity Trial
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2018
At a glance
- Drugs Idelalisib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- 13 Jun 2018 Planned initiation date changed from 2 May 2018 to 2 Jul 2018.
- 16 Apr 2018 Planned initiation date changed from 2 Apr 2018 to 2 May 2018.
- 29 Mar 2018 Planned initiation date changed from 26 Mar 2018 to 2 Apr 2018.